Tumor-specific positron emission tomography imaging in patients: [ 18F] fluorodeoxyglucose and beyond

David A. Mankoff, Janet F. Eary, Jeanne Link, Mark Muzi, Joseph G. Rajendran, Alexander M. Spence, Kenneth Krohn

Research output: Contribution to journalArticle

101 Scopus citations

Abstract

Biochemical and molecular imaging of cancer using positron emission tomography (PET) plays an increasing role in the care of cancer patients. Most clinical work to date uses the glucose analogue [18F] fluorodeoxyglucose (FDG) to detect accelerated and aberrant glycolysis present in most tumors. Although clinical FDG PET has been used largely to detect and localize cancer, more detailed studies have yielded biological insights and showed the utility of FDG as a prognostic marker and as a tool for therapeutic response evaluation. As cancer therapy becomes more targeted and individualized, it is likely that PET radiopharmaceuticals other than FDG, aimed at more specific aspects of cancer biology, will also play a role in guiding cancer therapy. Clinical trials designed to test and validate new PET agents will need to incorporate rigorous quantitative image analysis and adapt to the evolving use of imaging as a biomarker and will need to incorporate cancer outcomes, such as survival into study design.

Original languageEnglish (US)
Pages (from-to)3460-3469
Number of pages10
JournalClinical Cancer Research
Volume13
Issue number12
DOIs
Publication statusPublished - Jun 15 2007
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this